Q-omics provides the consensus-scored ZFAND4 profile across patient tissues and cancer cell-line models. ZFAND4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZFAND4 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, ZFAND4 RNA expression shows 20,065 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where ZFAND4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZFAND4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZFAND4 survival associations across molecular data types. ZFAND4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZFAND4 RNA expression–survival associations across cancer types. High ZFAND4 expression shows unfavorable associations in LGG and KICH, but favorable associations in KIRC, MESO, LUAD and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for ZFAND4 RNA expression.
This table summarizes ZFAND4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ZFAND4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZFAND4 shows lower tumor expression in KICH, THCA, COAD and LUSC and higher tumor expression in LIHC and STAD. The KICH box plot shows higher ZFAND4 RNA expression in normal versus tumor tissue (log2 FC = −1.427, t-test p < 0.001).
This table shows molecular features associated with ZFAND4 in patient tissues and cancer cell lines. In patient samples, ZFAND4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZFAND4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
